Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Illumina; Cancer Genetics; PDI; and More

NEW YORK (GenomeWeb) – Illumina will join the S&P 500 Index following the close of trading on Nov. 18. The firm also will be added to the S&P 500 Global Industry Classification Standard Life Science Tools & Services Sub-Industry index. Illumina is replacing Sigma-Aldrich, which is nearing completion of its acquisition by Merck KGaA, in the S&P 500.

Cancer Genetics has closed its previously announced public offering of 3,000,000 shares of its common stock with five-year warrants to purchase 3,000,000 shares of common stock at an exercise price of $5.00 per share at a combined price to the public of $4.00. The Rutherford, New Jersey-based molecular diagnostics firm said it expects gross proceeds of $12 million and net proceeds of $10.5 million after expenses from the offering.

PDI said that its Interpace Diagnostics business brought in third quarter revenues of $2.5 million compared with $47,000 for Q3 2014. The Parsippany, New Jersey-based molecular diagnostics and services firm recently said it would sell off its biomedical commercialization and marketing services business to Publicis Group for up to roughly $48 million and focus on its molecular diagnostics business. It also said that it would take on the name of its Interpace Diagnostics Group following closure of the deal.

Overall, PDI had revenues of $36.6 million for Q3 versus $28.3 million for Q3 2014. Its net loss was $4.9 million, or $.31 per share, up from a loss of $4.3 million, or $.29 per share.

Molecular Health said this week that it has opened an office in Berlin, Germany to meet demand for its suite of digital health services. The Heidelberg, Germany-based informatics firm, which also has an office in Boston, generates individualized analysis and clinical interpretation for evidence-based targeted therapy identification.

Enterome Bioscience said that it has inked a collaborative agreement with Gustave Roussy, a comprehensive cancer center based in Villejuif, France, to develop drugs and non-invasive monitoring tools for the gut microbiome in immuno-oncology applications. Paris-based Enterome is developing diagnostics and personalized therapies for microbiome-related diseases.

Cold Spring Harbor Laboratory said this week that it raised $4.5 million at its 10th Double Helix Medals Dinner in New York. The funds will support its research and education programs, it said. The dinner honored journalist and advocate for cancer screening Katie Couric, 23andMe CEO Anne Wojcicki, and Calico CSO David Botstein, who also previously served as director of the Lewis-Sigler Institute for Integrative Genomics at Princeton University.

Next Bio-Research Services announced this week that it has launched operations from its headquarters in Chester, Virginia. The firm is providing pharmacogenomics and molecular genetic testing for cancer and other diseases. It noted that it operates under Good Clinical Laboratory Practices and Good Laboratory Practices and is CLIA certified.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.